0|chunk|Entrapment of H1N1 Influenza Virus Derived Conserved Peptides in PLGA Nanoparticles Enhances T Cell Response and Vaccine Efficacy in Pigs
0	53	61 Peptides	Chemical	CHEBI_16670
0	65	69 PLGA	Chemical	CHEBI_53374
0	70	83 Nanoparticles	Chemical	CHEBI_50803
0	CHEBI-CHEBI	CHEBI_16670	CHEBI_53374
0	CHEBI-CHEBI	CHEBI_16670	CHEBI_50803
0	CHEBI-CHEBI	CHEBI_53374	CHEBI_50803

1|chunk|Pigs are believed to be one of the important sources of emerging human and swine influenza viruses (SwIV). Influenza virus conserved peptides have the potential to elicit crossprotective immune response, but without the help of potent adjuvant and delivery system they are poorly immunogenic. Biodegradable polylactic-co-glycolic acid (PLGA) nanoparticle (PLGA-NP) based vaccine delivery system enhances cross-presentation of antigens by the professional antigen presenting cells. In this study, Norovirus P particle containing SwIV M2e (extracellular domain of the matrix protein 2) chimera and highly conserved two each of H1N1 peptides of pandemic 2009 and classical human influenza viruses were entrapped in PLGA-NPs. Influenza antibody-free pigs were vaccinated with PLGA-NPs peptides cocktail vaccine twice with or without an adjuvant, Mycobacterium vaccae whole cell lysate, intranasally as mist. Vaccinated pigs were challenged with a virulent heterologous zoonotic SwIV H1N1, and one week later euthanized and the lung samples were analyzed for the specific immune response and viral load. Clinically, pigs vaccinated with PLGA-NP peptides vaccine had no fever and flu symptoms, and the replicating challenged SwIV was undetectable in the bronchoalveolar lavage fluid. Immunologically, PLGA-NP peptides vaccination (without adjuvant) significantly increased the frequency of antigen-specific IFN secreting CD4 and CD8 T cells response in the lung lymphocytes, despite not boosting the antibody response both at pre-and post-challenge. In summary, our data indicated that nanoparticlemediated delivery of conserved H1N1 influenza peptides induced the virus specific T cell response in the lungs and reduced the challenged heterologous virus load in the airways of pigs.
1	133	141 peptides	Chemical	CHEBI_16670
1	235	243 adjuvant	Chemical	CHEBI_60809
1	330	334 acid	Chemical	CHEBI_37527
1	336	340 PLGA	Chemical	CHEBI_53374
1	342	354 nanoparticle	Chemical	CHEBI_50803
1	426	434 antigens	Chemical	CHEBI_59132
1	455	462 antigen	Chemical	CHEBI_59132
1	573	580 protein	Chemical	CHEBI_16541
1	630	638 peptides	Chemical	CHEBI_16670
1	781	789 peptides	Chemical	CHEBI_16670
1	832	840 adjuvant	Chemical	CHEBI_60809
1	1140	1148 peptides	Chemical	CHEBI_16670
1	1303	1311 peptides	Chemical	CHEBI_16670
1	1333	1341 adjuvant	Chemical	CHEBI_60809
1	1639	1647 peptides	Chemical	CHEBI_16670
1	CHEBI-CHEBI	CHEBI_16670	CHEBI_60809
1	CHEBI-CHEBI	CHEBI_16670	CHEBI_37527
1	CHEBI-CHEBI	CHEBI_16670	CHEBI_53374
1	CHEBI-CHEBI	CHEBI_16670	CHEBI_50803
1	CHEBI-CHEBI	CHEBI_16670	CHEBI_59132
1	CHEBI-CHEBI	CHEBI_16670	CHEBI_16541
1	CHEBI-CHEBI	CHEBI_60809	CHEBI_37527
1	CHEBI-CHEBI	CHEBI_60809	CHEBI_53374
1	CHEBI-CHEBI	CHEBI_60809	CHEBI_50803
1	CHEBI-CHEBI	CHEBI_60809	CHEBI_59132
1	CHEBI-CHEBI	CHEBI_60809	CHEBI_16541
1	CHEBI-CHEBI	CHEBI_37527	CHEBI_53374
1	CHEBI-CHEBI	CHEBI_37527	CHEBI_50803
1	CHEBI-CHEBI	CHEBI_37527	CHEBI_59132
1	CHEBI-CHEBI	CHEBI_37527	CHEBI_16541
1	CHEBI-CHEBI	CHEBI_53374	CHEBI_50803
1	CHEBI-CHEBI	CHEBI_53374	CHEBI_59132
1	CHEBI-CHEBI	CHEBI_53374	CHEBI_16541
1	CHEBI-CHEBI	CHEBI_50803	CHEBI_59132
1	CHEBI-CHEBI	CHEBI_50803	CHEBI_16541
1	CHEBI-CHEBI	CHEBI_59132	CHEBI_16541

